Our data indicate that disruption of Atm/Atmin function not only inhibits GBM initiation in Trp53-deficient animals, but also reduces the tumorigenic potential of established human glioma cells, suggesting that ATM inhibitors might be valuable tools in GBM therapy. This evidence concerns the gene ATM and central nervous system cancer.